CA-USERTESTING
27.1.2021 03:02:09 CET | Business Wire | Press release
Collecting fast customer feedback has become mission-critical when competing in what is a very new and different business world. The ability to empathize with customers and understand how their buying behaviors have changed has never been more important than it is today. UserTesting , a leading provider of on-demand human insight , today announced several new capabilities designed to help companies meet the ever-evolving needs of their customers, with more test types that can give a greater understanding of how they organize and prioritize information, and interpret experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005448/en/
The January 2021 Product Release includes new test types for both web and mobile experiences, plus interactive visualization capabilities in the form of click maps, designed to reduce the amount of time it takes to review and analyze data.
With UserTesting’s latest release, companies can:
Understand how customers organize information and prioritize needs to deliver what they want
Card sorting helps users group, label, and describe information more effectively. UserTesting customers can now run closed, open, and hybrid card sort tests to gather insight into how to organize content and optimize their information architecture. With card sorting, companies can now more easily build experiences that put the customers’ needs first and make it easier for them to find what it is they want.
The prioritization matrix provides objective evidence to help teams prioritize tasks and projects. Not only does this reduce organizational risk by ensuring teams use customer feedback to focus on the most important tasks, but it also helps teams gain internal alignment faster with unbiased feedback directly from customers.
Leverage new test types to understand how your product, digital, and mobile iOS app experiences are resonating with customers
Developers can gather feedback on ease-of-use and perceived value before releasing apps on the App Store® online store with support for TestFlight® software public links. We’ve made it possible for you to do so with zero modifications to your project, zero lines of code, and zero configuration. Any team can easily gather qualitative feedback from real customers while they record their entire mobile screen - providing valuable input into how users interact with your app, and where you can optimize the experience.
System usability scale plus (SUS+) helps companies evaluate the usability of a product through a standardized template. This enables tracking improvements over time with longitudinal studies or easily comparing product usability to competitive products. Optional questions also allow users to measure promoter score and adjective rating.
Save time during post-test analysis with powerful and interactive visualizations
Click maps provide an interactive visual representation of all participant clicks and inputs on websites and hosted prototypes. This saves time during post-test analysis by helping companies quickly evaluate critical site interactions and then drill down further to get additional context and watch customers explain their thought process as they complete tasks and navigate sites.
"Companies are having to change and adapt at record speeds. The shift to a digital-first strategy, combined with rapidly changing consumer sentiment, has made collecting customer feedback vital to the process of designing, building, and marketing experiences,” said Kaj van de Loo, CTO at UserTesting. "Our latest offerings focus on empowering product managers, marketers, UX researchers, and designers with the tools to help them collect, prioritize, and analyze feedback so that they can build experiences that resonate with their customers, even when customer attitudes and behaviors are rapidly changing.”
Credit Notice
App Store® and TestFlight® are registered trademarks of Apple Inc.
About UserTesting
UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform , companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting customers including more than half of the world’s top brands. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
